Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 5Unknown 2Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Head & Neck 1Dermatologic 1

Conditions

Neoplasms 5Breast Neoplasms 5Depression 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Anxiety Disorders 3Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Polycystic Ovary Syndrome 2Lung Neoplasms 2Infertility 2Fatigue 2Carcinoma, Squamous Cell 2Carcinoma, Hepatocellular 2Advanced Solid Tumor 2Urologic Neoplasms 1Stress, Psychological 1Stomach Neoplasms 1Skin Neoplasms 1Sezary Syndrome 1Sexual Dysfunction, Physiological 1Sarcoma, Kaposi 1Sarcoma 1Pulmonary Disease, Chronic Obstructive 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pneumoperitoneum 1Peritoneal Neoplasms 1Periampullary Tumors 1

Interventions

Cyclophosphamide 17fludarabine 13Dexamethasone 12Cisplatin 11Rituximab 10Gemcitabine 9Paclitaxel 7Lenalidomide 7Decitabine 7Cytarabine 7Bendamustine Hydrochloride 7fludarabine phosphate 6N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 6Etoposide 6Carboplatin 6Bortezomib 6Radiotherapy 5Injections 5Azacitidine 5camrelizumab 4apatinib 4Valproic Acid 4Thalidomide 4Procarbazine 4Oxaliplatin 4Drug Therapy 4Antilymphocyte Serum 4tislelizumab 3pomalidomide 3liposomal doxorubicin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Recurrence × Therapeutics × Clear all
NCT05845632 2023-08-16

Time to Treatment and Disease-free Survival of Patients With High-risk Head-neck Cutaneous Squamous Cell Carcinoma

Maastricht University Medical Center

Unknown
965 enrolled
DermatologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Squamous Cell, Neoplasm Metastasis, Recurrence, Skin Neoplasms

NCT03770988 2019-02-22

A Trial to Evaluate the Efficacy of Poziotinib, Pan HER Inhibitor in Recurrent/Metastatic Esophageal Cancer (R/M ESCC)

Yonsei University

Phase 2 Unknown
49 enrolled

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡